Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-06-24
2011-12-27
Whiteman, Brian (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500
Reexamination Certificate
active
08084436
ABSTRACT:
Compounds, compositions and methods are provided for modulating the expression of SGLT2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SGLT2. Methods of using these compounds for modulation of SGLT2 expression and for diagnosis and treatment of diseases and conditions associated with expression of SGLT2 are provided.
REFERENCES:
patent: 5240847 (1993-08-01), Heckl et al.
patent: 5366878 (1994-11-01), Pederson et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6133246 (2000-10-01), McKay et al.
patent: 6150101 (2000-11-01), Grotendorst et al.
patent: 6162616 (2000-12-01), Shyjan
patent: 6211440 (2001-04-01), Briggs et al.
patent: 6284538 (2001-09-01), Monia et al.
patent: 6414126 (2002-07-01), Ellsworth et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 6537751 (2003-03-01), Cohen et al.
patent: 6582908 (2003-06-01), Fodor et al.
patent: 6809193 (2004-10-01), McKay et al.
patent: 6875747 (2005-04-01), Iversen et al.
patent: 6965025 (2005-11-01), Gaarde et al.
patent: 7273932 (2007-09-01), LaBarbera et al.
patent: 7507810 (2009-03-01), Karras et al.
patent: 2002/0052326 (2002-05-01), Washburn
patent: 2002/0137708 (2002-09-01), Bennett et al.
patent: 2003/0040497 (2003-02-01), Teng et al.
patent: 2003/0055019 (2003-03-01), Shimkets et al.
patent: 2003/0083280 (2003-05-01), Crooke et al.
patent: 2003/0087411 (2003-05-01), Bird et al.
patent: 2003/0223975 (2003-12-01), Tonks et al.
patent: 2003/0232336 (2003-12-01), Curtis et al.
patent: 2004/0162249 (2004-08-01), Liang et al.
patent: 2005/0032693 (2005-02-01), Gerritsen et al.
patent: 2005/0053981 (2005-03-01), Swayze et al.
patent: 2005/0059629 (2005-03-01), Gaarde et al.
patent: 2005/0107325 (2005-05-01), Manoharan et al.
patent: 2005/0191653 (2005-09-01), Freier et al.
patent: 2006/0063722 (2006-03-01), Washburn et al.
patent: 2007/0238866 (2007-10-01), Deshpande et al.
patent: 2007/0299028 (2007-12-01), Siwokowski et al.
patent: 1293569 (2003-03-01), None
patent: 1308459 (2003-05-01), None
patent: WO 97/29780 (1997-08-01), None
patent: WO 99/60012 (1999-11-01), None
patent: WO 99/66959 (1999-12-01), None
patent: WO 00/13706 (2000-03-01), None
patent: WO 00/18918 (2000-04-01), None
patent: WO 00/27868 (2000-05-01), None
patent: WO 00/35936 (2000-06-01), None
patent: WO 01/29217 (2001-04-01), None
patent: WO 02/096927 (2002-12-01), None
patent: WO 2004/016754 (2004-02-01), None
patent: WO 2005/038013 (2005-04-01), None
patent: WO 2005/042552 (2005-05-01), None
Agrawal et al., “Pharmacokinetics, Biodistrubution, and Stability of Oligodexynucleotide Phosphorothioates in Mice” PNAS (1991) 88:7595-7599.
Arakawa et al., “Improved Diabetic Syndrome in C57BL/KsJ-db/db Mice by Oral Administration of the Na-Glucose Cotransporter Inhibitor T-1095” Br. J. Pharmacol. (2001) 132:578-586.
Brown et al., “Glucose Transporters: Structure, Function, and Consequences of Deficiency” J. Inherit. Metab. Dis. (2000) 23:237-246.
Chin “On the Preparation and Utilization of Isolated and Purified Oligonucleotides” Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on Mar. 14, 2002.
Dang et al., “Oncogenic Alterations of Metabolism” TIBS (1999) 24:68-72.
European Supplementary Search Report for Application No. EP 04800679.5 dated Mar. 6, 2008.
Garay et al., “Inhibition of hypoxia/reoxygenation-induced apoptosis by an antisense oligonucleotide targeted to JNK1 in human kidney cells” Biochemical Pharmacology (2000) 59:1033-1043.
Geary et al., “Pharmacokinetics of Phosphorothioate Antisense Oligodeoxynucleotides” curr. Opin. Investig. Drugs (2001) 2:562-573.
Geary et al., “Pharmacokinetic Properties of 2′-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats” J. Pharm. Exp. Therap. (2001) 296:890-897.
Hediger te al., “Molecular Genetics of the Human Na/Glucose Cotransporter” Klin. Wochenschr. (1989) 67:843-846.
International Search Report for Application No. PCT/US04/36620 dated Nov. 23, 2005.
Ishikawa et al., “SGLT Gene Expression in Primary Lung Cancers and their Metastatic Lesions” Jpn. J. Cancer Res. (2001) 92:874-879.
Kanai et al., “The Human Kidney Low Affinity Na/Glucose Cotransporter SGLT2” J. Clin. Invest. (1994) 93:397-404.
Kong et al., “Cloning and Expression of a Mammalian Na/Amino Acid Cotransporter with Sequence Similarity to Na/Glucose Cotransporters” J. Biol. Chem. (1993) 268:1509-1512.
Ma et al., “Synthetic oligonucleotides as therapeutics: the coming of age” Biotechnology Annual Review (2000) 5:155-196.
MacKenzie et al., “Biophysical Characteristics of the Pig Kidney Na/Glucose Cotransporter SGLT2 Reveal a Common Mechanism for SGLT1 and SGLT2” J. Biol. Chem. (1996) 271:32678-32683.
MacKenzie et al., “SAAT1 is a Low Affinity Na/Glucose Cotransporter and not an Amino Acid Transporter” J. Biol. Chem. (1994) 269:22488-22491.
Maier et al., “Enzymatic Degradation of Varius Antisense Oligonucleotides: Monitoring and Fragment Identification by MECC and ES-MS” Biomed. Pept. Proteins Nucleic Acids (1995) Vik, 1, 235-242.
Nawano et al., “Hyperglycemia Contributes Insulin Resistance in Hepatic and Adipose Tissue but not Skeletal Muscle of ZDF Rats” Am. J. Physiol. Endocrinol. Metab. (2000) 278:E535-E543.
New England Biolabs, 1998/1999 Catalog, pp. 121 and 284.
Oku et al., “T-1095, An Inhibitor of Renal Na/Glucose Cotransporters, May Provide a Novel Approach to Trating Diabetes” Diabetes (1999) 48:1794-1800.
Oku et al., “Antidiabetic Effect of T-1095, An Inhibitor of Na-Glucose Cotransporter, In Neonatally Streptozotocin-Trated Rats” Eur. J. Pharmacol. (2000) 391:183-192.
Pontoglio et al., “HNF-1a Controls Renal Glucose Reabsorption in Mouse and Man” EMBO Reports (2000) 1:359-365.
Reynolds et al., “Rational siRNA design for RNA interference” Nature Biotechnology (2004) 22(3):326-330.
Shaw et al., “Modified Deoxyoligonucleotides Stable to Exonuclease Degradation in Serum” Nucleic Acids Res. (1991) 19:747-750.
Tabatabai et al., “Differential Regulation of Mouse Kidney Sodium-Dependent Transporters mRNA by Cadmium” Toxicol. Appl. Pharmacol. (2001) 177:163-173.
Tsujihara et al., “Na/Glucose Cotransporter (SGLT) Inhibitors as Antidiabetic Agents. 4. Synthesis and Pharmacological Properties of 4′-Dehydroxyphlorizin Derivatives Substitutes on the B Ring” J. Med. Chem. (1999) 42:5311-5324.
Turner et al., “Heterogeneity of Sodiu,-Dependent D-Glucose Transport Sites Along the Proximal Tubule: Evidence from Vesicle Studies” Am. J. Physiol. (1982) 242:F406-F414.
Turner et al., “Stoichiometric Studies of the Rental Outer Cortical Brush Border Membrane p-Glucose Transporter” J. Membrane Biol. (1982) 67:73-80.
Van Den Heuvel et al., “Autosomal Recessive Renal Glucosuria Attributable to a Mutation in the Sodium Glucose Cotransporter (SGLT2)” Hum. Genet. (2002) 111:544-547.
Vestri et al., “Changes in Sodium or Glucose Filtration Rate Modulate Expression of Glucose Transporters in Renal Proximal Tubular Cells of Rat” J. Membrane Biol. (2001) 182:105-112.
Wells et al., “Cloning of a Human Kidney cDNA with Similarity to the Sodium-Glucose Cotransporter” Am. J. Physiol. (1992) 263:F459-F465.
Wells et al., “Localization of the Na/Glucose Cotransporter Gene SGLT-2 to Human Chromosome 16 Close to the Centromere” Genomics (1993) 17:787-789.
Woolf et al., “The Stability, Toxicity and Effectiveness of Unmodified and Phosphorothioate Antisense Oligodeoxynucleotides in Xenopus Oocytes and Embryos” Nucleic Acids Res. (1990) 18:1763-1769.
Wright, “Renal NA-Glucose Cotransporters” Am. J. Physiol. Renal Physiol (2001) 280:F10-F18.
You et al., “Molecular Characteristics
Freier Susan M.
Monia Brett P.
Siwkowski Andrew M.
Wancewicz Edward
Watts Lynnetta
Isis Pharmaceuticals , Inc.
Isis Pharmaceuticals, Inc. Patent Dept.
Whiteman Brian
LandOfFree
Modulation of SGLT2 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of SGLT2 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of SGLT2 expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4313525